Adjuvant olaparib  - High risk early breast cancer with BRCA1 or BRCA2 germline mutation

Bull Cancer. 2023 Sep 14:S0007-4551(23)00340-5. doi: 10.1016/j.bulcan.2023.07.004. Online ahead of print.NO ABSTRACTPMID:37716861 | DOI:10.1016/j.bulcan.2023.07.004

Source: Bulletin du Cancer - September 16, 2023 Category: Cancer & Oncology Authors: Ma ëva Bonneau Audrey Bellesoeur Source Type: research